Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced the initiation of a Phase 1 study of INT-767, a dual farnesoid X ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE